Ozempic maker Novo Nordisk to cut 11% of workforce

Novo Nordisk is undertaking a significant global restructuring, cutting 9,000 jobs or 11% of its workforce, to address intensifying competition in the weight-loss drug market. This strategic move is projected to generate $1.25 billion in annualized savings by 2026, earmarked for reinvestment into its core diabetes and obesity R&D and commercial initiatives, despite incurring a similar one-off restructuring cost and lowering its 2025 operating profit growth forecast to 4-10%. Investors reacted positively to the announcement, with shares rising, signaling approval of the company's shift towards a leaner, more focused operational model.

Analysis

Novo Nordisk is executing a significant global restructuring by cutting 9,000 jobs, or 11% of its workforce, as a direct response to intensifying competition in the weight-loss drug market, particularly from Eli Lilly's Mounjaro and emerging compounded alternatives. This strategic pivot aims to generate approximately $1.25 billion in annualized savings by the end of 2026, which will be redirected into its core diabetes and obesity R&D and commercial initiatives. This move signals a reversal of a recent hiring spree and an effort to create a leaner, more performance-driven organization under its new CEO. While the company will absorb a one-off restructuring cost of roughly $1.25 billion, a more material development for the near-term outlook is the downward revision of its full-year 2025 operating profit growth forecast to 4-10% from a previous 10-16%. Despite this guidance cut, the positive investor reaction, evidenced by a 3% rise in its Danish-listed stock, indicates market approval инфекции for the proactive cost management and long-term strategic refocus on innovation to defend its market leadership.

Key Decisions for Investors

• Investors should weigh the near-term negative impact of a lowered 2025 operating profit growth forecast against the market's apparent approval of the long-term strategy to enhance R&D and competitiveness through cost savings.
• The restructuring explicitly acknowledges the competitive threat from Eli Lilly, so portfolio managers should closely monitor market share data and R&D pipeline developments for both companies as key performance indicators.
• Consider the execution risk associated with this large-scale restructuring, as the projected $1.25 billion in annualized savings is contingent on successful implementation while the associated costs will materially impact 2024 results.